|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's Range||34.69 - 34.98|
|52 Week Range||29.05 - 40.01|
|Beta (3Y Monthly)||1.55|
|PE Ratio (TTM)||29.96|
|Earnings Date||Apr 29, 2019|
|Forward Dividend & Yield||0.85 (2.45%)|
|1y Target Est||38.47|
AMSTERDAM, Feb. 18, 2019 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of Philips Zenition, its new mobile C-arm imaging platform. Mobile C-arms are X-ray systems that are brought into the operating room (OR) to provide live image guidance during a wide range of surgeries including orthopedic, trauma and vascular procedures. The Zenition mobile C-arm platform brings together innovations in image capture, image processing, ease-of-use and versatility pioneered on Philips' highly successful Azurion platform.
- Miami Cancer Institute, part of Baptist Health South Florida, implements Philips' cloud-based comprehensive genomics platform to inform cancer treatment options through advanced diagnostic testing (next ...
Comprehensive image and information management solution features new pediatric innovative workflow and integration with Philips Forcare for enhanced interoperability across health systems and hospitals ...
- Only decision-support solution that combines clinical informatics and genomic sequencing information to help identify healthcare associated infections - Recent study shows an 87 percent reduction in ...
Philips' scalable, secure and interoperable health information management portfolio features AI-powered smart enterprise systems, devices, software and services Integrated solutions seamlessly connect ...
Do you actually read privacy policies before you click accept? If you're like most Americans, probably not. But what is in those privacy policies may surprise you. We have privacy lawyers and a cybersecurity expert read privacy policies from big companies and share what is inside.
- EPIQ Elite for General Imaging enhances clinical performance and delivers a new ultrasound solution tailored to the needs of vascular assessment - EPIQ Elite for Obstetrics & Gynecology provides exceptional ...
- Next generation enterprise-wide health informatics platform now includes IntelliSpace Precision Medicine Oncology, IntelliSpace Genomics and interoperable clinical data sharing with IntelliSpace Exchange ...
On a per-share basis, the Amsterdam-based company said it had profit of 82 cents. Earnings, adjusted for one-time gains and costs, came to 87 cents per share. The medical imaging equipment maker posted ...
Dutch health technology company Philips on Tuesday said it is moving "hundreds of millions" of euros worth of production from the United States to China and vice versa, to mitigate the effects of the ongoing trade war between the two countries. "These are serious changes to our supply chains", Chief Executive Frans van Houten told reporters.
The trade war between Washington and Beijing is forcing Dutch health technology company Philips to move "hundreds of millions" of euros worth of production from the United States to China, and vice versa, to avoid punitive tariffs. "This is not peanuts", Chief Executive Frans van Houten told reporters on Tuesday. Philips, whose healthcare products range from high-tech toothbrushes to medical imaging systems, stuck to an earlier prediction that increased trade tariffs would cut around 60 million euros ($69 million) from core profits this year.
NV (PHIA.AE) said Tuesday that fourth-quarter net profit decreased 22% and announced the start of a new 1.5 billion euro ($1.71 billion) share-buyback program. The Dutch electronics producer said net profit was EUR673 million compared with EUR860 million a year earlier. On a comparable basis, sales were up 5%, Philips said.
The spike, which does not reflect the thousands of new downtown jobs announced last year alone, also raises fresh questions about whether downtown's water, sewer and roads can sustain such a burst of action over the long term.
NewYork-Presbyterian Hospital and Philips collaborate to enhance care with remote patient monitoring system AMSTERDAM and NEW YORK , Jan. 24, 2019 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA), ...
The Food and Drug Administration sounded an alarm Thursday about certain drug-coated stents and balloons used to treat coronary and peripheral artery disease.
The Philips and American Heart Association Connected Pulse Program first-of-a kind initiative, combines education, training and technology for an integrated customized solution in major metropolitan areas ...